227 related articles for article (PubMed ID: 34001647)
1. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry.
Walker UA; Tilson HH; Hawkins PN; Poll TV; Noviello S; Levy J; Vritzali E; Hoffman HM; Kuemmerle-Deschner JB;
RMD Open; 2021 May; 7(2):. PubMed ID: 34001647
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
3. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
Brogan PA; Hofer M; Kuemmerle-Deschner JB; Koné-Paut I; Roesler J; Kallinich T; Horneff G; Calvo Penadés I; Sevilla-Perez B; Goffin L; Lauwerys BR; Lachmann HJ; Uziel Y; Wei X; Laxer RM
Arthritis Rheumatol; 2019 Nov; 71(11):1955-1963. PubMed ID: 31161734
[TBL] [Abstract][Full Text] [Related]
4. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.
Kuemmerle-Deschner JB; Kallinich T; Henes J; Kortus-Götze B; Oommen PT; Rech J; Krickau T; Weller-Heinemann F; Horneff G; Janda A; Foeldvari I; Schuetz C; Dressler F; Borte M; Hufnagel M; Meier F; Fiene M; Andreica I; Weber-Arden J; Blank N
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38360038
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
[TBL] [Abstract][Full Text] [Related]
7. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
8. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
Yokota S; Imagawa T; Nishikomori R; Takada H; Abrams K; Lheritier K; Heike T; Hara T
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):19-26. PubMed ID: 27974104
[TBL] [Abstract][Full Text] [Related]
10. Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry.
Tilson H; Primatesta P; Kim D; Rauer B; Hawkins PN; Hoffman HM; Kuemmerle-Deschner J; van der Poll T; Walker UA
Orphanet J Rare Dis; 2013 Sep; 8():139. PubMed ID: 24016338
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Miyamoto T; Izawa K; Masui S; Yamazaki A; Yamasaki Y; Matsubayashi T; Shiraki M; Ohnishi H; Yasumura J; Kawabe T; Miyamae T; Matsubara T; Arakawa N; Ishige T; Takizawa T; Shimbo A; Shimizu M; Kimura N; Maeda Y; Maruyama Y; Shigemura T; Furuta J; Sato S; Tanaka H; Izumikawa M; Yamamura M; Hasegawa T; Kaneko H; Nakagishi Y; Nakano N; Iida Y; Nakamura T; Wakiguchi H; Hoshina T; Kawai T; Murakami K; Akizuki S; Morinobu A; Ohmura K; Eguchi K; Sonoda M; Ishimura M; Furuno K; Kashiwado M; Mori M; Kawahata K; Hayama K; Shimoyama K; Sasaki N; Ito T; Umebayashi H; Omori T; Nakamichi S; Dohmoto T; Hasegawa Y; Kawashima H; Watanabe S; Taguchi Y; Nakaseko H; Iwata N; Kohno H; Ando T; Ito Y; Kataoka Y; Saeki T; Kaneko U; Murase A; Hattori S; Nozawa T; Nishimura K; Nakano R; Watanabe M; Yashiro M; Nakamura T; Komai T; Kato K; Honda Y; Hiejima E; Yonezawa A; Bessho K; Okada S; Ohara O; Takita J; Yasumi T; Nishikomori R;
Arthritis Rheumatol; 2024 Jun; 76(6):949-962. PubMed ID: 38268504
[TBL] [Abstract][Full Text] [Related]
12. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
14. Real-world safety and effectiveness of canakinumab in patients with cryopyrin-associated periodic fever syndrome: a long-term observational study in Japan.
Hosono K; Kato C; Sasajima T
Clin Exp Rheumatol; 2022 Sep; 40(8):1543-1553. PubMed ID: 36106540
[TBL] [Abstract][Full Text] [Related]
15. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.
Kuemmerle-Deschner JB; Haug I
Ther Adv Musculoskelet Dis; 2013 Dec; 5(6):315-29. PubMed ID: 24294305
[TBL] [Abstract][Full Text] [Related]
16. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study.
Jaeger VK; Hoffman HM; van der Poll T; Tilson H; Seibert J; Speziale A; Junge G; Franke K; Vritzali E; Hawkins PN; Kuemmerle-Deschner J; Walker UA
Rheumatology (Oxford); 2017 Sep; 56(9):1484-1491. PubMed ID: 28482054
[TBL] [Abstract][Full Text] [Related]
17. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.
Elmi AA; Wynne K; Cheng IL; Eleftheriou D; Lachmann HJ; Hawkins PN; Brogan P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):36. PubMed ID: 31287007
[TBL] [Abstract][Full Text] [Related]
18. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
19. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations.
Ahmadi N; Brewer CC; Zalewski C; King KA; Butman JA; Plass N; Henderson C; Goldbach-Mansky R; Kim HJ
Otolaryngol Head Neck Surg; 2011 Aug; 145(2):295-302. PubMed ID: 21493283
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]